STK11 and neoplasm: As the poor prognosis is recognized in SMARCA4-deficient tumors, the presence of frequent co-mutation with other tumor suppressor genes, such as STK11 and/or KEAP1, further dampens the regrettable overall survival and shortens the progression free survival outcome of the disease.